Suzanne L. Topalian

Bloomberg (United States) — United States

Medicine · Health Sciences

101h-index96.2kcitations358works9.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(203), Immunotherapy and Immune Responses(150), CAR-T cell therapy research(86), Immune Cell Function and Interaction(64), T-cell and B-cell Immunology(38)

Publications355 total

Figure S2 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
2025Open Access
Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
2025Open Access
Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort
Annals of Oncology·2025
599 The MATRiX trial: a multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1-refractory merkel cell carcinoma
Regular and Young Investigator Award Abstracts·2025Open Access
The MATRiX trial: A multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1–refractory Merkel cell carcinoma.
Journal of Clinical Oncology·2025· 2 cited
A minimal gene set characterizes TIL specific for diverse tumor antigens across different cancer types
Nature Communications·2025· 9 citedOpen Access
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study
Journal of Clinical Oncology·2025· 15 citedOpen Access
Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care
Journal for ImmunoTherapy of Cancer·2025· 11 citedOpen Access
Immunology of Melanoma
2024
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
Journal of Clinical Oncology·2024· 10 citedOpen Access
935 A minimal gene set characterizes tumor-reactive TIL specific for multiple classes of tumor antigens across different cancer types
Regular and Young Investigator Award Abstracts·2024Open Access
695 Phase 2 study of nivolumab and ipilimumab in combination with sirolimus and prednisone in kidney transplant recipients with selected unresectable or metastatic cutaneous cancers
Regular and Young Investigator Award Abstracts·2024Open Access
Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy
Journal for ImmunoTherapy of Cancer·2024· 7 citedOpen Access
936 Transcriptional programming of CD8+ TIL specific for an oncogenic polyomavirus in Merkel cell carcinoma
Regular and Young Investigator Award Abstracts·2024Open Access
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial
The Lancet Oncology·2024· 48 cited
Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade
Journal of Translational Medicine·2024· 9 citedOpen Access
Cancer-specific CD8 T cell frequency at baseline in blood correlates with response to PD-1 blockade in Merkel cell carcinoma
immuneACCESS·2024
Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma
Cell Reports Medicine·2024· 24 citedOpen Access
T antigen–specific CD8+ T cells associate with PD-1 blockade response in virus-positive Merkel cell carcinoma
Journal of Clinical Investigation·2024· 15 citedOpen Access
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers
Journal of Clinical Oncology·2024· 46 citedOpen Access
page 1 of 18Next →

Frequent Co-authors

Drew M. Pardoll(23), Steven A. Rosenberg(18), Janis M. Taube(15), James Chih‐Hsin Yang(14), Richard M. Sherry(13), Julie R. Brahmer(12), Douglas J. Schwartzentruber(10), Claudia A. Seipp(9), Sharon Mavroukakis(9), Charles G. Drake(8), Robert A. Anders(8), Nicholas P. Restifo(8), Richard E. Royal(8), Udai S. Kammula(8), F. Stephen Hodi(7), William H. Sharfman(7), Mario Sznol(7), Donald E. White(7), John D. Powderly(6), Richard D. Carvajal(6)